Last reviewed · How we verify
U87 autologous CAR T-cell
U87 autologous CAR T-cell is a Small molecule drug developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd. It is currently in Phase 1 development.
At a glance
| Generic name | U87 autologous CAR T-cell |
|---|---|
| Sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- U87 autologous CAR T-cell CI brief — competitive landscape report
- U87 autologous CAR T-cell updates RSS · CI watch RSS
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd portfolio CI
Frequently asked questions about U87 autologous CAR T-cell
What is U87 autologous CAR T-cell?
U87 autologous CAR T-cell is a Small molecule drug developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd.
Who makes U87 autologous CAR T-cell?
U87 autologous CAR T-cell is developed by Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (see full Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd pipeline at /company/shanghai-unicar-therapy-bio-medicine-technology-co-ltd).
What development phase is U87 autologous CAR T-cell in?
U87 autologous CAR T-cell is in Phase 1.